Nuevas dianas terapéuticas en el tratamiento de la degeneración macular asociada a la edad

Muñoz-Ramón, Pablo; Martínez, P. Hernández; Muñoz‐Negrete, Francisco J.

doi:10.1016/j.oftal.2019.09.011

Cited by 9 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At a size of ~26 kDa, the humanized single-chain antibody fragment brolucizumab may provide enhanced tissue penetration, clearance, and drug delivery characteristics compared to more traditional anti-VEGF agents [ 51 ]. By comparison, ranibizumab and aflibercept have molecular weights of 48 and 115 kDa, respectively [ 52 ].…”

Section: Emerging Neovascular Amd Therapiesmentioning

confidence: 99%

New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD)

Patel

Sheth²

2021

JCM

View full text Add to dashboard Cite

Age-related macular degeneration (AMD) is one of the most common causes of vision loss. Advanced forms of AMD are seen in primarily two types—neovascular AMD (nAMD) with the presence of choroid neovascularization and non-neovascular AMD (nnAMD) with geographic atrophy. Neovascular AMD is characterized by choroidal neovascularization (CNV), which leads to a cascade of complications, including exudation, leakage, and ultimately fibrosis with photoreceptor loss. Inhibition of VEGF represents the current standard of care. However, there is a tremendous gap between the outcomes in randomized clinical trials and real-world settings. New agents for nAMD might offer the potential to improve treatment outcomes and reduce treatment of frequent intravitreal injections. We summarize all the newer molecules, their pivotal clinical trial results, and their unique mechanisms of action; these include longer-acting agents, combination strategies, sustained release, and genetic therapies.

show abstract

Section: Emerging Neovascular Amd Therapiesmentioning

confidence: 99%

New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD)

Patel

Sheth²

2021

JCM

View full text Add to dashboard Cite

show abstract

“…The function of angiopoietins (ANG) on CNV is complex; however, studies reflect that it majorly depends on the composition of inflammatory factors in the ocular environment [136]. Theoretically, ANG-1 is present in copious quantities in vascular surroundings, and its primary function is the maintenance of homeostasis by inhibition of cellular proliferation, permeation, and exudation.…”

Section: Angiopoietin Inhibitorsmentioning

confidence: 99%

Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD)

Sarkar

Junnuthula

Dyawanapelly

2021

IJMS

View full text Add to dashboard Cite

Age-related macular degeneration (AMD) is the leading cause of vision loss in geriatric population. Intravitreal (IVT) injections are popular clinical option. Biologics and small molecules offer efficacy but relatively shorter half-life after intravitreal injections. To address these challenges, numerous technologies and therapies are under development. Most of these strategies aim to reduce the frequency of injections, thereby increasing patient compliance and reducing patient-associated burden. Unlike IVT frequent injections, molecular therapies such as cell therapy and gene therapy offer restoration ability hence gained a lot of traction. The recent approval of ocular gene therapy for inherited disease offers new hope in this direction. However, until such breakthrough therapies are available to the majority of patients, antibody therapeutics will be on the shelf, continuing to provide therapeutic benefits. The present review aims to highlight the status of pre-clinical and clinical studies of neovascular AMD treatment modalities including Anti-VEGF therapy, upcoming bispecific antibodies, small molecules, port delivery systems, photodynamic therapy, radiation therapy, gene therapy, cell therapy, and combination therapies.

show abstract

Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology

Formica

Alfonso

Palma

2021

Pharmacology Res & Perspec

View full text Add to dashboard Cite

Currently, biological drug therapy for ocular angiogenesis treatment is based on the administration of anti‐VEGF agents via intravitreal route. The molecules approved with this purpose for ocular use include pegaptanib, ranibizumab, and aflibercept, whereas bevacizumab is commonly off‐label used in the clinical practice. The schedule dosage involves repeated intravitreal injections of anti‐VEGF agents to achieve and maintain effective concentrations in retina and choroids, which are administrated as solutions form. In this review article, we describe the features of different anti‐VEGF agents, major challenges for their ocular delivery and the nanoparticles in development as delivery system of them. In this way, several polymeric and lipid nanoparticles are explored to load anti‐VEGF agents with the aim of achieving sustained drug release and thus, minimize the number of intravitreal injections required. The main challenges were focused in the loading the molecules that maintain their bioactivity after their release from nanoparticulate system, followed the evaluation of them through studies of formulation stability, pharmacokinetic, and efficacy in in vitro and in vivo models. The analysis was based on the information published in peer‐reviewed published papers relevant to anti‐VEGF treatments and nanoparticles developed as ocular anti‐VEGF delivery system.

show abstract

Nuevas dianas terapéuticas en el tratamiento de la degeneración macular asociada a la edad

Cited by 9 publications

References 40 publications

New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD)

New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD)

Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD)

Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology

Contact Info

Product

Resources

About